Castle Creek Pharma has assembled a robust and well diversified portfolio of innovative and high potential late stage drug candidates in development for the treatment of a number of important diseases. Castle Creek Pharma’s products are advancing rapidly through development and have the potential to enter the market within 2-3 years.

Orphan Dermatology

Epidermolysis Bullosa Simplex

  • Epidermolysis bullosa simplex (EBS) is the most common form of epidermolysis bullosa, a rare dermatologic condition where patients (many of them children) have a genetic defect that compromises the structural integrity of their skin, making it particularly fragile and prone to blistering throughout their bodies. The disease can be severely debilitating and there are no treatment options currently available.
  • CCP-020 (diacerein 1% ointment) is a new drug in development for the treatment of EBS. It is believed to block an important inflammatory signaling pathway in EBS.
  • The DELIVERS study is evaluating the safety and efficacy of CCP-020 (diacerein 1% ointment) for the treatment of EBS. For more information, visit http://deliversebs.com/ or see the study listing at ClinicalTrials.gov.